经动脉内化疗灌注联合放疗治疗晚期上颌牙龈鳞状细胞癌的预后因素和治疗结果。
Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy.
机构信息
Departments of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama City, Kanagawa, Japan.
Department of Dentistry and Oral Surgery, Yamato Municipal Hospital, Yamato City, Kanagawa, Japan.
出版信息
Head Neck. 2019 Jun;41(6):1777-1784. doi: 10.1002/hed.25607. Epub 2019 Jan 29.
BACKGROUND
The aim of this study was to evaluate the prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma (SCC) treated with intra-arterial infusion chemotherapy concurrent with radiotherapy.
METHODS
A total of 46 patients were reviewed retrospectively in this study. The treatment schedule comprised intra-arterial chemotherapy (total, 60 mg/m docetaxel and 150 mg/m cisplatin) and three-dimensional computed tomography based, daily conventional radiotherapy (total, 60 Gy/30 fr) for 6 weeks.
RESULTS
The median follow-up period was 40 months (range, 3-110 months). The 3-year overall survival and locoregional control rates for all patients were 64.3% and 84.3%, respectively. The OS rate of the patients with N0-1 was significantly higher than that of the patients with N ≥ 2 (P < .05). No grade 5 toxicities were observed.
CONCLUSIONS
Intra-arterial infusion chemotherapy concurrent with radiotherapy was effective for advanced maxillary gingival SCC.
背景
本研究旨在评估经动脉内化疗联合放疗治疗晚期上颌牙龈鳞状细胞癌（SCC）的预后因素和治疗结果。
方法
本研究回顾性分析了 46 例患者。治疗方案包括动脉内化疗（总量为 60mg/m 的多西他赛和 150mg/m 的顺铂）和基于三维计算机断层扫描的每日常规放疗（总量为 60Gy/30 次），持续 6 周。
结果
中位随访时间为 40 个月（范围 3-110 个月）。所有患者的 3 年总生存率和局部区域控制率分别为 64.3%和 84.3%。N0-1 患者的 OS 率明显高于 N≥2 患者（P<.05）。未观察到 5 级毒性。
结论
经动脉内化疗联合放疗对晚期上颌牙龈 SCC 有效。
Zotero 插件